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Abstract
The prognosis for postcardiac arrest patients remains very bleak, not only because of anoxic-ischemic neurological
damage, but also because of the “postcardiac arrest syndrome,” a phenomenon often severe enough to cause
death before any neurological evaluation. This syndrome includes all clinical and biological manifestations related
to the phenomenon of global ischemia-reperfusion triggered by cardiac arrest and return of spontaneous
circulation. The main component of the postcardiac arrest syndrome is an early but severe cardiocirculatory
dysfunction that may lead to multiple organ failure and death.
Cardiovascular support relies on conventional medical and mechanical treatment of circulatory failure.
Hemodynamic stabilization is a major objective to limit secondary brain insult. When the cause of cardiac arrest is
related to myocardial infarction, percutaneous coronary revascularization is associated with improved prognosis;
early angiographic exploration should then be discussed when there is no obvious extracardiac cause. Therapeutic
hypothermia is now the cornerstone of postanoxic cerebral protection. Its widespread use is clearly recommended,
with a favorable risk-benefit ratio in selected population. Neuroprotection also is based on the prevention of
secondary cerebral damages, pending the results of ongoing therapeutic evaluations regarding the potential
efficiency of new therapeutic drugs.
Introduction
Sudden death remains a major public health issue, despite
improvements in prehospital management and standardi-
zation of advanced life support through wide diffusion of
international guidelines [1]. Both incidence and poor prog-
nosis are striking: according to official statistics, approxi-
mately 100,000 people are supported for out-of-hospital
cardiac arrest (OHCA) in the United States each year.
However, it is estimated that the real number of sudden
death is two to three times higher. Even more problematic,
less than 10% of patients admitted to the hospital after
successfully resuscitated OHCA will leave the hospital
without major neurological impairments.
For patients who survive the initial phase of prehospi-
tal care, the course is usually marked by two types of
events:
1. Syndrome originally described as an early reperfu-
sion syndrome (or “postresuscitation disease”), which
usually appears between the 4th and 24th hour in
the form of a stereotypical feature whose extreme
form involves a state of shock, high fever, and severe
biological disorders [2].
2. Poor neurological prognosis because two thirds of
patients who survive the early phase will subse-
quently develop neurofunctional sequellae, which
sometimes progress toward a postanoxic vegetative
state and delayed death [3].
The frequency and intensity of these complications
depend largely on the delay of initial treatment, the effi-
ciency of resuscitation, and the time elapsed between
collapse and return of spontaneous circulation (ROSC).
At that time, CA and its resuscitation is the clinical
situation closest to the phenomenon of “ischemia-reper-
fusion,” well known from experimental models [4].
Moreover, this is the only medical situation that enables
measurement of clinical acute consequences of global
ischemia, targeting simultaneously all tissues and organs.
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observed features and justifies the therapeutic interven-
tions that must be performed to achieve a favorable
neurological evolution. Optimizing postresuscitation
care is of paramount importance, because it represents
the last link of the survival chain.
Pathophysiology of postcardiac arrest syndrome
The pathophysiology of postcardiac arrest syndrome is
complex and remains partially understood (Figure 1). It
seems, however, dominated by a global ischemia-reper-
fusion phenomenon (affecting all organs) and a nonspe-
cific activation of the systemic inflammatory response.
During ischemia (phase of “no flow”), reduced oxygen
supply is offset by lower metabolic needs. However, if
cell metabolism remains requested or if the ischemia
period is prolonged, the decrease of ATP synthesis leads
to a plasma membrane depolarization, opening of vol-
tage-dependent calcium channels sarcolemne, and fall of
mitochondrial membrane potential. Schematically these
phenomena result in an increase of intracytoplasmic cal-
cium concentration responsible for cellular damage.
Thus, it is during the phase of “no flow” that the first
cell and tissue damage will occur. Reperfusion (phase of
“low flow”), contemporary to the restoration of blood
flow (created by chest compression, or spontaneous), is
responsible for the formation of oxygen radical species,
including superoxide anion (￿ O2-), hydrogen peroxide
(H2O2) and the radical hydroxyl (￿ OH). The latter, par-
ticularly cytotoxic, carries for most functional and struc-
tural lesions causing cell death [4]. Indeed, it inactivates
cytochromes, alters membrane transport proteins, and
induces phenomena of membrane lipid peroxidation. In
vivo demonstration was provided by studying plasma of
out-of-hospital CA survivors, which induced acute and
major endothelial toxicity, due to an acute pro-oxidant
state that occurs within the cells, and illustrated by a
decrease in antioxidant activity [5]. Disseminated vascu-
lar endothelium damages explain that this phenomenon
of ischemia-reperfusion evolves toward systemic inflam-
mation: production of cytokines (IL-1, IL-6, IL-8, TNF-
a), complement activation, synthesis of metabolites of
arachidonic acid, expression of leukocyte adhesion mole-
cules by endothelial cells are all stimuli for activation,
and chemotaxis of polymorphonuclear neutrophils at
the origin of the inflammatory response. Sequestration
of activated neutrophils in the lungs and other organs is
a major engine for development of multiple organ fail-
ure. It is plausible that infectious lesions of digestive ori-
gin are involved, in relation to bacterial translocation
from altered gastrointestinal mucosa. It would explain
the high levels of plasma endotoxin observed in the
Figure 1 Schematic pathophysiology of postresuscitation damages.
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temic inflammatory response associates with changes in
coagulation, generating secondary endothelial damage,
in turn responsible for thrombosis and increased capil-
lary permeability [6]. Experimental models of CA sup-
port the pathophysiological hypothesis of worsening of
visceral lesions that occur during the reperfusion phase
and extend over the first hours, explaining the efficiency
of some delayed therapeutic interventions (as therapeu-
tic hypothermia). In humans, there is an activation of
the inflammatory reaction associated with clinical fea-
tures that are very similar to those observed during
severe sepsis [7]. Coagulation abnormalities have been
identified, involving a significant activation of coagula-
tion factors, whereas endogenous anticoagulants (antith-
rombin, protein S and C) are decreased [8]. This
intravascular coagulation can be implicated in the gen-
esis of microvascular abnormalities, which in turn lead
to more visceral lesions. Of note these coagulation
abnormalities are particularly common in patients who
die quickly from a post-resuscitation shock.
Clinical features
The postcardiac arrest syndrome presents a set of rela-
tively stereotyped events [9]. Its intensity varies but is
roughly proportional to the duration of “no flow” and
“low flow,” as well as difficulty encountered during
initial resuscitation [10]. The cardiocirculatory failure
usually dominates the clinical picture, even if it often
leads to multiorgan failure (MOF). The decrease of cere-
bral perfusion, caused by these hemodynamic distur-
bances, might further impair the neurological prognosis
of these patients.
Postcardiac arrest shock
The postcardiac arrest shock, initially described by
Negovsky in 1975, is a mixed shock, with cardiogenic
and vasodilatory components [2] and is characterized by
a severe but reversible systolic dysfunction. Left ventri-
cular dysfunction usually begins early, within minutes
after ROSC, and is completely reversible within 48 to 72
hours. It takes the form of myocardial systolic and dia-
stolic dysfunctions, even in the absence of coronary
cause. The experimental evidence of this early, intense,
and transient myocardial dysfunction after CA could be
confirmed in humans. Indeed, Laurent et al. described
the hemodynamic profile of postcardiac arrest shock
[11]. In this study including 148 consecutive patients
after a successfully resuscitated CA, 73 patients (49%)
developed an early shock (within a median time of 8
hours after initial resuscitation) and were explored inva-
sively with pulmonary artery catheter. Upon admission
to the ICU, these patients exhibited a significant
decrease in angiographic left ventricular ejection
fraction, regardless of the etiology of CA. This shock
was characterized by a low cardiac output and normal
or low left filling pressures. Interestingly, in agreement
with experimental data, the cardiac index improved
quickly in patients with shock, from 2.1 l/min/m
2 (med-
ian value at the 8
th hour) to 3.2 l/min/m
2 at the 24
th
hour, and up to 3.7 l/min/m
2 at the 72
th hour. The per-
sistence of a low cardiac index was associated with early
death, usually in a setting of MOF. But the circulatory
failure does not appear to be related only to myocardial
dysfunction. Indeed, despite the fast improvement of
contractile function in survivors, this study also showed
that vasopressors often had to be maintained until the
72
th hour, in association with important fluid infusion
to maintain adequate filling pressures. Thus, these data
support the existence of an early and intense myocardial
failure, usually regressive within 48 hours, secondarily
associated with a severe vasodilatation, as a result of the
generalized inflammatory syndrome, itself well docu-
mented after CA [6]. Obviously, this has to be distin-
guished from the focal hypocontractility caused by a
coronary thrombosis, which evolves on its own. The cir-
culatory failure might also be favored by the occurrence
of relative adrenal insufficiency, as observed during sep-
tic shock: clinical data show that approximately half of
patients have relative adrenal insufficiency similar to
what can be observed in septic shock. Among these
patients, shock-related deaths seem to be more frequent
in the group of those with adrenal insufficiency [12].
Neurological failure
The anoxic-ischemic neurological damages remain the
leading cause of deaths occurring in patients initially
resuscitated from CA. This neurological impairment can
usually be detected from the third day after initial resus-
citation. However, the dogma that the brain damage
would be only due to injuries occurring contemporarily
to circulatory interruption has been widely challenged
during the past decade. Clinical studies that confirmed
the efficiency of therapeutich y p o t h e r m i ad e s p i t ei t s
“late” initiation, as regard to the onset of CA, support
the existence of a worsening process during the reperfu-
sion period. Indeed, neurological damage is initiated
during circulatory interruption but also is accentuated
during the reperfusion phase. Experimental and clinical
studies show that the cerebral blood flow is decreased
during the postcardiac arrest syndrome, associated with
a decrease in cerebral oxygen extraction. The reduction
of cerebral blood flow, which seems to be related to a
transient increase in cerebral vascular resistance, will be
corrected within 72 hours. Among survivors, the nor-
malization of cerebral blood flow is accompanied by an
increase in cerebral oxygen extraction, reflecting the
recovery of the physiological coupling of these two
Mongardon et al. Annals of Intensive Care 2011, 1:45
http://www.annalsofintensivecare.com/content/1/1/45
Page 3 of 11parameters [13]. However, in patients with lethal brain
injuries, the difference in coupling between cerebral
blood flow and extraction appears gradually and finally
results in a “luxury” perfusion.
Other organ failures
Without specific and prompt treatment, postcardiac
arrest shock usually leads to a multiple organ failure
and early death. Acute renal and respiratory dysfunc-
tions occur in approximately 40-50% of patients resusci-
tated from CA. Hypoxemia (a consequence of
pulmonary edema, but also lung contusion, atelectasia,
or aspiration), cardiogenic shock, acute renal failure, and
liver failure may of course worsen the prognosis and
delay neurological recovery. The digestive tract insult
often is underestimated, due to the lack of bedside tool
to investigate its function; however, its alteration should
not be considered, both as a victim of the circulatory
f a i l u r ea n da sas e c o n ds o u r c eo fo r g a nf a i l u r et h r o u g h
translocation and major source of endotoxemia.
Infectious issues
Many mechanisms that occur after CA make cardiopul-
monary resuscitation survivors prone to infectious com-
plications. Loss of airways’ protection, coma, pulmonary
contusion, emergency airway and vascular access,
mechanical ventilation, and ischemia-reperfusion
increase the risk for infection. The diagnosis is extre-
mely complex, due to many clinical, biological, and radi-
ological confounding factors. Moreover, therapeutic
hypothermia plays a dual role by promoting infection
and by impairing both host defences and usual infec-
tious criteria. Recently developed biomarkers, such as
procalcitonin, perform poorly in the assessment of septic
complications [14]. We recently demonstrated that two
thirds of CA survivors presented infectious complica-
tions during their ICU stay and may be favored by
hypothermia. Despite increase in mechanical ventilation
duration and length of stay, mortality and neurological
outcome were not impaired by infectious events [15]. If
antibioprophylaxis is not recommended, infectious com-
plications should be cautiously tracked, especially when
therapeutic hypothermia is employed.
Therapeutic aspects
The therapeutic management of the postcardiac arrest
syndrome has two main goals: the initial treatment of
shock and organ failures, and the optimization of cere-
bral protection. These two aspects are obviously very
intricate, initial treatment having the essential interest to
allow bringing the majority of patients to neurological
evaluation, under hemodynamic stability conditions. The
medical algorithm that we apply in our unit is displayed
in Figure 2.
Cardiovascular management
Shock treatment
Except in special cases, the impossibility of early reliable
neurological assessment justifies the introduction of organ
support during the initial postresuscitation phase. When
initially controlled, the postresuscitation shock is usually
reversible within 48 to 72 hours and treatments differ little
from inflammatory shock associated with heart failure.
Regarding myocardial dysfunction, the treatments are the
usual drugs of acute heart failure. The favorable effect of
dobutamine on myocardial dysfunction after CA was con-
firmed by experimental models, demonstrating improved
systolic and diastolic functions [16]. However, the restora-
tion of ventricular contractility is accompanied by a dose-
dependent tachycardia, which may cause a rise in myocar-
dial oxygen consumption. The use of epinephrine often is
necessary in the most severe forms of shock after cardiac
arrest, because ventricular dysfunction is usually asso-
ciated with severe vasoplegia at this phase. However, in
addition to its usual side effects, epinephrine exhibits an
increase in myocardial oxygen consumption and a poten-
tially deleterious activation of metabolic intracellular sig-
nals. Association of dobutamine and norepinephrine could
be preferred. In this situation, the correction of absolute
or relative hypovolemia is crucial and should, whenever
possible, precede the introduction of vasoconstrictors.
Other inotropic drugs have been tested (phosphodiesterase
inhibitors, levosimendan) but without demonstrating
superior efficiency. Widely used for ischemic cardiogenic
shock, intra-aortic counterpulsation reduces cardiac work
by reducing left ventricular afterload and improves tissue
perfusion and diastolic coronary perfusion. During post-
cardiac arrest shock, its interest is not clearly established
[17]. The use of circulatory support by extracorporeal
membrane oxygenation after cardiac arrest is experiencing
growth and shows promising results on mortality [18,19].
However, its indications appear limited because of the
cumbersome logistics of such therapy requiring a specia-
lized team, in the setting of an unknown neurological out-
come. Alternative techniques for minimally invasive
circulatory support, such as the miniaturized system
Impella
® (Cardiosystems Impella AG, Aachen, Germany)
that uses a micropump assistance of the left ventricular
introduced via the femoral artery, should be evaluated in
this context.
Correction of hemodynamic disorders
The particularities of postcardiac arrest shock suggest a
clinical feature close to septic shock, suggesting a bene-
ficial effect of extracorporeal treatment referred as “anti-
inflammatory.” A pilot study showed that renal replace-
ment therapy by high-volume hemofiltration (with or
without hypothermia) could help to reduce early mortal-
ity related to hemodynamic failure after cardiac arrest
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of cardiovascular failure in some patients. However, these
preliminary data do not allow recommending the routine
use of this technique in postcardiac arrest syndrome, and
further studies are required in this way. Regarding the
level of arterial pressure that should be targeted during
this period, the single study conducted on this point
failed to show significant difference between patients
maintained at a mean arterial pressure > 100 mmHg vs. <
100 mmHg in the first 2 hours after ROSC [21]. Hemo-
dynamic monitoring using at least arterial catheter seems
essential; an echocardiography performed within the first
24 hours seems useful, not only for the etiological diag-
nosis but also to optimize the hemodynamic status of
these patients. However, no monitoring device has defini-
tively proven its superiority in this setting.
Coronary revascularization
Acute coronary syndrome is the most common cause of
out-of-hospital cardiac arrest in adults. A systematic
application of coronary angiography on hospital arrival
for all survivors of CA found a recent coronary occlusion
in 49% of cases [22]. Clinical data (cardiovascular risk
factors chest pain) and ECG perform poorly to predict
coronary occlusion; in a recent study, 96% of patients
with ST-segment elevation on the ECG performed after
ROSC, and 58% of patients without ST-segment elevation
had at least one significant coronary artery lesion [23].
Moreover, there was an independent association between
successful dilatation of a coronary artery responsible for
CA and hospital survival. Consequently, the indication of
coronary angiography should be considered widely, as
well as the prehospital referring of the patient to a center
able to provide coronary angiography if required: current
guidelines recommend performing immediate coronary
revascularization in patients with OHCA [24]. The
results obtained in routine clinical practice on research
and systematic treatment of acute coronary occlusion in
survivors of cardiac arrest in ischemic context also are
particularly encouraging [23].
Figure 2 Early postcardiac arrest management.
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The existence of further cerebral damage during the
reperfusion phase encouraged intense research on the
benefit of treatments designed to limit the neurological
consequences of the postcardiac arrest syndrome.
Therapeutic hypothermia
Many experimental data show that mild hypothermia
can exert neuroprotective effects through multiple
mechanisms of action: decrease of cerebral metabolism,
reduction of apoptosis and mitochondrial dysfunction,
slowing of the cerebral excitatory cascade, decrease of
local inflammatory response, reduction of free oxygen
radicals production, and decrease of vascular and mem-
brane permeability. The convergent experimental data
were confirmed by two landmark clinical studies pub-
lished in 2002 [25,26]. In both trials, the implementation
of mild hypothermia achieved a survival rate without
major sequel in approximately 40-50% of a highly
“selected” population (OHCA with an initial rhythm of
ventricular fibrillation in front of a bystander).
Hypothermia was achieved in both cases by external
cooling methods (blanket, ice packs), associated with
routine use of neuromuscular blocking agents. At the
targeted levels of hypothermia (32-34°C), theoretical
adverse effects (arrhythmias, coagulopathy, infection)
were very rare. A trend toward greater frequency of
bleeding and infectious events was observed but was
greatly overweighed by the neurological and survival
benefit. The publication of these two studies was deci-
sive and led to a rapid change in international recom-
mendations on the management of patients surviving
after CA. It is now strongly recommended to use mod-
erate hypothermia routinely (32-34°C) for 12 to 24
hours in any comatose adult successfully resuscitated
after OHCA caused by ventricular fibrillation/tachycar-
dia [1]. In patients presenting with an initial nonshock-
able rhythm, the level of evidence is weaker, and some
recent data suggest a lack of neurological benefit [27].
Considering that the risk-benefit ratio is sufficiently
favorable, it is reasonable to discuss the indication for
treatment on a case-by-case basis. Finally, no single
cooling method has been shown to be superior in terms
of clinical outcomes.
Neuroprotective drugs
Despite numerous attempts, no drug has clearly demon-
strated its ability in the early or late phase of resuscita-
tion to reduce the consequences of cerebral anoxo-
ischemia after CA, despite encouraging animal data and
early administration after ROCS. Similarly, the different
sedative agents have not proven their efficiency. Thus,
apart from special situations (therapeutic hypothermia
for instance), there is no argument for recommending
the routine use of pharmacological agents in CA survi-
vors. Currently, several molecules with cytoprotective
effects during ischemia-reperfusion phenomena are
investigated. The more advanced research are available
for cyclosporine, which shows promising preliminary
results through inhibition of the opening of the mito-
chondrial permeability-transition pores; erythropoietin is
as well under consideration, with a strong experimental
background of polyfactorial neuroprotection and
encouraging clinical outcomes [28,29].
Prevention of secondary cerebral damages
Achieving and maintaining a perfect homeostasis, parti-
cularly in terms of metabolism, are the major goals of
post cardiac arrest management.
Hematosis control
Hypoxemia should be avoided by increasing the oxygen
fraction of inspired gas to maintain arterial oxygen
saturation > 92% to maintain a sufficient oxygen trans-
port to peripheral tissues. It is not necessary to set a tar-
get of “supraphysiological” PaO2. Moreover, hyperoxia is
a matter of debate [26,30]. The level of PaCO2,w h i c hi s
completely controlled by the ventilatory settings in this
sedated and sometimes paralyzed patient, is exposed to
significant variations. Hypocapnia, meanwhile, should be
avoided because it causes a reduction of cerebral blood
flow. After animal CA, ROSC is accompanied by a tran-
sient cerebral hyperemia by approximately 15-30 min-
utes, followed by a secondary and more prolonged
decline. In a canine model of CA using therapeutic
hypothermia, hyperventilation appeared to worsen the
neurological outcome [31]. In addition, hyperventilation
may be responsible for increased intracranial pressure
by increasing positive end-expiratory pressure. Conver-
sely, hypercapnia, leading to cerebrovascular vasodilata-
tion and increased intracranial pressure, should be
banned. Overall, despite the absence of clinical studies
that specifically address the ventilatory settings, it seems
logical to maintain a PaCO2 within normal limits [9].
For this, it is necessary to monitor the quality of ventila-
tion using, whenever possible, measurement of expira-
tory tidal CO2 and regular monitoring of arterial blood
gases, especially during cooling and warming phases,
which significantly alter production of CO2.
Metabolic control
The correction of electrolyte disturbances is essential
and special attention should be given to the one that
may participate in the recurrence of CA or worsening of
organ dysfunction. A potential survival benefit was
recently demonstrated, when tight-controlled glycemia
was applied to an overall population of patients
admitted to surgical and medical intensive care. Co-
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strated as beneficial on the neurological recovery in an
animal model of CA [32]. Even if there is a strong asso-
ciation between high blood glucose levels and adverse
neurological outcome after CA, conclusions on associa-
tion or causality cannot be drawn. The increased fre-
quency of hypoglycemia observed during tight control
glycemia should be kept in mind before extending this
therapeutic approach in patients with severe brain
damage and possibly more sensitive to the deleterious
consequences of a hypoglycemic episode. Thus, in the
absence of additional data, it is not possible to recom-
mend the use of tight control glycemia in patients with
postcardiac arrest shock. Such an attitude should be
demonstrated in terms of benefit/risk ratio. However,
converging data underline that blood glucose variability
more seriously impairs the outcome of critically ill
patients rather than the mean level of glycemia. This
observation has recently been confirmed in cardiac
arrest survivors [33], so that attention should probably
be paid to avoid such glycemia fluctuations.
Outcome prediction
Immediately after CA, no clinical signs or investigations
accurately predict the patient’s outcome. During the
first hours and days after ROSC, half of these patients
will subsequently suffer from a postresuscitation disease,
which can include a severe shock leading by itself to
death. As mentioned earlier, shock should be treated
without limitation during the very first hours and days
to reach the adequate window for neurological evalua-
tion. Finally, brain death occurs in approximately 10% of
these patients a few days after CA because of cerebral
edema [34]. Those patients are dead and life support
will be stopped after completion of the organ-donation
process.
After ROSC, accurate prognostication can only occur
after 72 hours have elapsed from all factors that may
alter neurological evaluation. This last point is of parti-
cular importance if sedation and neuromuscular block-
ade were used in conjunction with therapeutic
hypothermia, because this treatment strategy must
extend the waiting period [35]. Thus, if hypothermia is
employed, it also is reasonable to use short-acting drugs.
All other usual confounding situations (medications,
hypothermia, and concomitant organ failure) must be
resolved before any prognostication process.
Tools to predict outcome during ICU stay
Accurate assessment of prognosis is necessary to iden-
tify patients who will really benefit from intensive care
and to avoid extending unnecessary treatments to those
who have no reasonable chance of recovery. Prognosti-
cation should always be based on a rigorous clinical
evaluation, which may include detailed neurological
examination. Because there is no specific clinical sign
that can predict outcome in the first few hours after
ROSC, reliable prognostic factors and assessment of the
ICU admission could be very useful. At this very early
stage, a few elements are however available, and their
accuracy are sometimes questionable. These elements
can be grouped roughly into four main categories:
intrinsic patient characteristics (age and comorbidities),
parameters reflecting the quality of prehospital care ("no
flow” and “low flow” durations), the etiology of CA, and
finally, some of the patient’s clinical characteristics:
- Intrinsic characteristics, including age, have a mod-
est prognostic weight on early survival [36];
- The speed and quality of prehospital care logically
have a major impact on the prognosis of patients. If
“no flow” and “low flow” durations are valuable
prognostic factors, with substantial mortality over
respectively 5 and 15 minutes [36], they cannot
carry a final decision element. In addition, the accu-
racy of the information collected often is question-
able in this context, which limits the scope of their
prognosis ability.
- Concerning the cause of CA, asphyxia, and to a
lesser degree, all extracardiac causes, are predictors
of poor prognosis. In contrast, sudden cardiac death,
occurring on a body properly oxygenated, is usually
associated with better prognosis. However, once
again, decisions cannot be made according to this
oversimplistic split.
The absence of pupillary light response is not suffi-
ciently predictive when it is sought on admission, due to
a high false-positive rate, which can reach 30% [37]. Sev-
eral additional clinical findings accurately predict poor
outcome: myoclonus status epilepticus within the first
24 hours, absence of pupillary responses within days 1
to 3 after CPR, absence of corneal reflexes within days 1
to 3 after CA, and absent or extensor motor responses
after 3 days [37,38]. Thus, the prognosis is invariably
poor in comatose patients with absent pupillary or cor-
neal reflexes, or absent or extensor motor responses 3
days after CA. On the opposite, single seizures and
sporadic focal myoclonus do not accurately predict poor
outcome. In the same way, although permanent status
epilepticus is associated with a mortality approaching
100%, exceptions have been reported.
Investigations that may enhance prognostication
In addition to physical examination, various methods
have been evaluated for assessing the neurological prog-
nosis of comatose CA victims. Electrophysiological tests
in coma consist of EEG and evoked/event-related
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(SSEPs) are the best diagnostic method for predicting
outcome in comatose patients. Bilateral absence of the
N20 component of the SSEPs with median nerve stimu-
lation recorded on days 1 to 3 or later after CA accu-
rately predicts a poor outcome [38]. Conversely, the
presence of the N20 response is not helpful to predict
outcome as many patients who fail to recover can have
preserved N20 responses.
Routine EEG examinations are not supported by the
results of the published reviews but should be used if
ongoing seizure activity is suspected. Generalized sup-
pression pattern, burst-suppression pattern with general-
ized epileptiform activity, or generalized periodic
complexes on a flat background are strongly but not
invariably associated with poor outcome [38].
Anoxo-ischemic cerebral insult is associated with the
blood release of various biomarkers and the peak plas-
matic level is thought to be correlated with the amount
of neuronal death. A large serum peak of neuron-speci-
fic enolase and/or S-100 protein is highly specific but
only moderately sensitive for predicting a poor neurolo-
gical outcome [38]. The search for a simple, reliable,
and readily available biological test remains an exciting
challenge [39], but clinical decisions with potentially
irreversible consequences should never rely on a single
marker.
Regarding routine neuroimaging techniques, CT-scan
imaging adds no information unless stroke, bleeding, or
trauma is suspected. Preliminary reports suggest that
magnetic resonance imaging could be used to determine
the prognosis of patients with diffuse cerebral anoxia
[40] but warrants further investigations.
End-of-life process after cardiac arrest
In a small number of distressing cases, patients regain
spontaneous circulation but remain in a persistent vege-
tative state. It can be stated that continued existence of
this state is not in the patient’s best interest even if the
only other alternative remains death. When this
approach is shared both by care providers and relatives,
end of life care must be considered: this consists in
withholding/withdrawing all invasive and supportive
care. Considering that most of these neurologically
impaired patients are mechanically ventilated, the deci-
sion to withdraw therapies will nearly always include a
statement about the pursuit of this assistance. When all
conditions are joined, it is suitable to plan an extubation
and the definitive withdrawal of respiratory assistance.
This should be performed in conjunction with all com-
fort care that can be provided in such a situation (pain
treatment, sedation). Decision to withdraw life-support
treatment and the modalities of this withdrawal must be
the conclusion of a collegial process between team and
proxies, and all must be made to avoid the family’sf e e l -
ing of responsibility. Such decisions must obviously
meet all the legal steps that exist in the country.
Mild and long-term outcome of survivors
Recurrence prevention
Studies that focus on patient outcome beyond the first
month after hospital discharge are limited. Historical
data are hardly comparable to the populations who have
benefited from recent progress in term of access to early
defibrillation and ICU management. The long-term
mortality is generally considered satisfactory, with a 5-
year survival of approximately 80% for patients leaving
ICU after CA due to ventricular arrhythmia [41]. This is
slightly lower than subjects of similar age but is similar
to patients of identical age and matched with
comorbidities.
The cardiac outcome, and primarily the risk for recur-
rence of sudden death, is obviously different depending
on the etiology of initial CA. Patients who experienced
ventricular arrhythmia have been widely studied because
of the availability of implantable cardioverter defibrilla-
tor (ICD). This last one significantly reduces the risk of
sudden death compared with antiarrhythmic drugs
[42,43], demonstrating clearly the benefit of ICD in
patients resuscitated from a ventricular arrhythmia. The
majority of cardiovascular mortality (including sudden
death) is observed within 12 to 24 months after the
initial arrhythmia [44]. During this period, systolic func-
tion is the best predictor of early recurrence. CA survi-
vors should therefore benefit from a comprehensive
etiological investigation. The depth and the means for
assessing the patient’s cardiovascular status and long-
term risk prognosis are obviously largely dependent on
the magnitude of neurological recovery. Other therapeu-
tic modalities are common with patients experiencing
cardiovascular disease, especially in patients with
ischemic disease, who constitute the majority of the sur-
vivors (Figure 3).
Sequels and quality of life
Beyond recurrence, quality of life and the possibility of
finding a social activity in patients sometimes young and
active often are poorly taken into consideration. Of the
681 patients studied after discharge from hospital for a
period of 6 months, 69% of them were considered to
have a good neurological recovery at discharge [45]. For
70% of patients followed, the neurological status
remained stable, or even improved, in 12% of cases; only
1% of the patients exhibited a decrease in neurological
performance. In this cohort, the 6-month mortality of
17% was mainly due to cardiovascular causes. To go
further, a fine evaluation of the quality of life was per-
formed 3 years after resuscitation from ventricular
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[41], which explores both physical and mental aspects.
R e s u l t sw e r es u p e r p o s a b l eo nt h eo n eo fam a t c h e d
population, except that survivors displayed a lower sense
of vitality. Hypoxic insult may nevertheless result in a
number of disorders considered as minor but having a
strong impact on quality of life, such as memory pro-
b l e m s .T h e ym a yb ee v e nm o r ef r e q u e n ti ny o u n g e r
patients than in older subjects. Overall, health status of
these patients is therefore considered as satisfactory
[46,47].
In recent years, interest in posttraumatic stress disor-
der (PTSD) has steadily increased in patients experien-
cing ICU admission [48]. CA survivors represent an
important potential source for development of PTSD. A
study compared the psychological status of patients who
experienced intrahospital cardiac arrest or a myocardial
infarction 9 months after the event and revealed that,
among survivors of cardiac arrest, 30% suffered from
anxiety, 15% depression, and 19% PTSD, whereas the
proportions observed were respectively 7%, 0%, and 7%
after acute myocardial infarction [49]. This study high-
lights the frailty of survivors of cardiac arrest and the
significant risk of emotional disorders [50]. Another
study showed that PTSD occurred in one third of survi-
vors of CA 45 months after the event [51]. Interestingly,
this study displayed that the only risk factor for PTSD
was age: the younger the patient, the more at risk he is
to suffer from PTSD. Conversely, according to the
study, pre- and intrahospital management of cardiac
arrest did not affect the onset of PTSD.
Conclusions
Major progress has occurred during the past 10 years in
the initial management of successfully resuscitated CA:
the development of a “chain of survival,” the availability
of automated external defibrillators in paramedical
teams and public places, and the innovations in the
resuscitation process gives hope for a further improve-
ment in early survival. This will be accompanied by a
steady increase in patients exposed to postcardiac-arrest
syndrome. A better understanding of this syndrome
undoubtedly transforms the last link of the survival
chain: from an attitude of observation, the hospital man-
agement now becomes active and might condition in
part the patient’sp r o g r e s si nt h es h o r ta n dl o n gt e r m .
The primary objective of such care is to obtain survival
with no or little neurological sequels. By influencing the
vital and functional prognosis of patients, cerebral pro-
tection is now an essential part of the management of
postcardiac-arrest patients. Currently, it relies mainly on
therapeutic hypothermia. In the future, new pharmaco-
logical and nonpharmacological treatments should con-
tribute to further improve the prognosis of these
patients.
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